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Background
Vaccinees in the Step Trial who were Ad5 seropositive at
baseline had a trend toward increased HIV infection [2.3-
fold increased incidence (CI:1.2–4.3)] (Lancet, 2008;
372(9653): 1881–93). To further explore the relationship
between HIV and Ad5, we investigated evidence of inci-
dent Ad5 infection and whether HIV infection was associ-
ated with increases in Ad5 neutralizing antibody (nAb)
titer in the absence of vaccination.
Methods
Sera were assayed using the Merck Ad5 nAb assay: positive
titer range 18 – 4,608. We assessed incident Ad5 infection
by measuring nAb titers at 52 weeks for 208 placebo recip-
ients who were seronegative (titer<18) at enrolment. We
next assessed the association between increases in Ad5
titer (which may suggest recent Ad5 infection) and inci-
dent HIV among placebo recipients. Ad5 titer was meas-
ured at the last pre-infection visit for 33 incident HIV cases
(both Ad5 seronegative and seropositive at enrolment)
and at the corresponding visit for 130 matched controls;
hazard ratios used the difference between Ad5 titer at
enrolment and this later time point.
Results
At 52 weeks following enrolment, we detected low posi-
tive Ad5 nAb titers in 4% (8/208) of seronegative enroll-
ees in the placebo group; titers ranged from 19–41,
(median 23.5). We next assessed whether serologic evi-
dence of Ad5 infection occurred at a higher rate in subjects
who acquired HIV infection. Ad5 nAb titers increased in
21% of cases compared to 31% in controls [hazard ratio:
0.792 (p = 0.665)].
Conclusion
The low incidence and magnitude of Ad5 nAb titer
increases in the placebo group suggest that Ad5 infections
occurred rarely, if at all, among study participants. In
addition, there was no evidence of an association between
HIV infection and increases in Ad5 titers in participants.
Thus, post-enrolment Ad5 infection is not a predisposing
factor for HIV acquisition in the placebo group of the Step
Trial.
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